Samsung Biologics Co Ltd (207940) - Total Liabilities

Latest as of September 2025: ₩6.16 Trillion KRW ≈ $4.17 Billion USD

Based on the latest financial reports, Samsung Biologics Co Ltd (207940) has total liabilities worth ₩6.16 Trillion KRW (≈ $4.17 Billion USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Samsung Biologics Co Ltd (207940) cash flow conversion to assess how effectively this company generates cash.

Samsung Biologics Co Ltd - Total Liabilities Trend (2014–2024)

This chart illustrates how Samsung Biologics Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check 207940 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.

Samsung Biologics Co Ltd Competitors by Total Liabilities

The table below lists competitors of Samsung Biologics Co Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
Advanced Info Service Public Company Limited BK:ADVANC	Thailand	฿312.99 Billion
Baidu Inc F:B1C	Germany	€159.43 Billion
Foshan Haitian Flavouring and Food Co Ltd SHG:603288	China	CN¥7.28 Billion
Hindustan Aeronautics Limited NSE:HAL	India	Rs860.27 Billion
Fresnillo plc F:FNL	Germany	€1.73 Billion
Kering SA PA:KER	France	€25.67 Billion

Liability Composition Analysis (2014–2024)

This chart breaks down Samsung Biologics Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Samsung Biologics Co Ltd market cap and net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.69	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.51	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.34	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Samsung Biologics Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Samsung Biologics Co Ltd (2014–2024)

The table below shows the annual total liabilities of Samsung Biologics Co Ltd from 2014 to 2024.

Year	Total Liabilities	Change
2024-12-31	₩6.43 Trillion ≈ $4.36 Billion	+3.47%
2023-12-31	₩6.22 Trillion ≈ $4.21 Billion	-18.19%
2022-12-31	₩7.60 Trillion ≈ $5.15 Billion	+155.05%
2021-12-31	₩2.98 Trillion ≈ $2.02 Billion	+63.19%
2020-12-31	₩1.83 Trillion ≈ $1.24 Billion	+17.23%
2019-12-31	₩1.56 Trillion ≈ $1.06 Billion	-14.67%
2018-12-31	₩1.82 Trillion ≈ $1.24 Billion	-43.09%
2017-12-31	₩3.21 Trillion ≈ $2.17 Billion	-7.07%
2016-12-31	₩3.45 Trillion ≈ $2.34 Billion	+8.32%
2015-12-31	₩3.19 Trillion ≈ $2.16 Billion	+339.42%
2014-12-31	₩724.97 Billion ≈ $491.30 Million	--

About Samsung Biologics Co Ltd

KO:207940 Korea Biotechnology

Market Cap

$31.37 Billion

₩46.29 Trillion KRW

Market Cap Rank

#842 Global

#16 in Korea

Share Price

₩1000000.00

Change (1 day)

+0.00%

52-Week Range

₩991000.00 - ₩1000000.00

All Time High

₩1000000.00